

Bioactivity and Therapeutic Potential of Plant Extracts in Cancer and Infectious Diseases

Simeon Pierre Chegaing Fodouop¹, Richard Tagne Simo¹, Jeremie Mbo Amvene¹, Emmanuel Talla², Paul Faustin Seke Etet³, Paul Takam⁴, Armel Herve Nwabo Kamdje¹, Jean-Marc Muller⁵

¹Department of Biomedical Sciences, Faculty of Sciences, University of Ngaoundere, Ngaoundere, Cameroon

²Department of Chemistry, Faculty of Sciences, University of Ngaoundere, Ngaoundere, Cameroon

³Department of Basic Health Sciences, College of Applied Medical Sciences, Qassim University, Buraydah, Saudi Arabia

⁴Department of Medicine, Section of Hematology, Stem Cell Research Laboratory, University of Verona, Verona, Italy

⁵University of Poitiers, Faculty of Science, Poitiers, France

Email address:

saafodouop@yahoo.fr (S. P. Chegaing Fodouop), richardsimotagne@yahoo.fr (R. Tagne Simo), jer_ambo@yahoo.fr (J. Mbo Amvene), tallae2000@yahoo.fr (E. Talla), paul.seke@gmail.com (P. F. Seke Etet), takoumba@yahoo.fr (P. Takam), kamdjewa@yahoo.fr (A. H. Nwabo Kamdje), jean.marc.muller@univ-poitiers.fr (J. M. Muller)

To cite this article:

Simeon Pierre Chegaing Fodouop, Richard Tagne Simo, Jeremie Mbo Amvene, Emmanuel Talla, Paul Faustin Seke Etet, Paul Takam, Armel Herve Nwabo Kamdje, Jean-Marc Muller. Bioactivity and Therapeutic Potential of Plant Extracts in Cancer and Infectious Diseases. *Journal of Diseases and Medicinal Plants*. Vol. 1, No. 1, 2015, pp. 8-18. doi: 10.11648/j.jdmp.20150101.12

Abstract: Medicinal plants have been used particularly in resource poor communities of the African continent as an alternative for the treatment of infectious diseases. Traditional medicine plays a critical role in treatment of chronic debilitating and life threatening conditions and infectious diseases. Cancer is one such condition whose therapeutic intervention is commonly through inexpensive traditional herbal remedies. Increasingly industrialised societies are developing drugs and chemotherapeutics from these traditional herbal plants. Plant biogeography determines the abundance and availability of medicinal plants which in turn determine their use by african communities. Recent findings of bioactivity and therapeutic potential of plant extracts in cancer and infectious diseases are herein summarized and discussed.

Keywords: Antioxidants, Chemotherapy, Medicinal Plants, Phytochemicals, Prophylaxis, Herbs, Natural Products, Cancer, Infectious Diseases

1. Introduction

Medicinal plants have been used particularly in resource poor communities of the African continent as an alternative for the treatment of infectious diseases [1], cancer [2] and other diseases [1,2]. Several findings on the chemotherapeutic potentials of plants have shown that they can be sources of antimicrobial compounds of value [3]. A typical example of such plants is *Garcinia kola*.

They contain large varieties of chemical substances that possess important therapeutic properties used in the treatment of many diseases. Plant extracts are rich source of terpenes, antioxidant phenolics, flavonoids and other biologically-active compounds. In modern medicine these compounds have been investigated for their anthelmintic and antioxidant activities in parasitized animals by neutralizing the free radicals and toxins formed in their blood, boost their immune system, and help fighting gastrointestinal parasites [4].

Natural bioactive compounds like phenols and flavonoids are the important secondary metabolites in plants having intrinsic properties that affect appearance, taste, odor and oxidative stability of plant based foods. These compounds also possess biological properties like antioxidant, anti-aging, anti-carcinogen, protection from cardiovascular, immune/autoimmune diseases and brain dysfunctions viz. Parkinson's, Alzheimer's, Huntington's diseases, etc [5,6]. Therapeutic potential of *A. absinthium* extract is directly related to total phenolic and flavonoids contents. These active metabolites especially from herbs are the interest subject of research, but their extraction as part of phytochemical or biological investigations presents specific challenges that must be addressed throughout the solvent extraction process. The present review summarizes and discusses the current understanding of bioactivity and therapeutic potential of plant extracts in cancer and infectious diseases.

2. Cancer and Infectious Diseases is There any Link Between Cancer and Infectious Diseases

Infection is considered as a major risk to develop cancer, among all newly cancer diagnosed in 2008, almost 16% were attributed to infection agents [7]. This percentage is most high in developing countries, probably due to the fact that they have a high incidence of infectious disease [8, 9]. Many infectious agents including viruses, parasites and bacteria are classified as group 1 carcinogenic agents by the International Agency for Research on Cancer (IARC). Epidemiological evidences and molecular mechanisms bridge a correlation between infections and cancer. For example, human cytomegalovirus (HCMV) is found in high percentage of glioblastoma patients, and the association of anti cancer therapy to antiviral therapy against HCMV increases median survival of patient with glioblastoma multiforme [10, 11]. In fact there are 7 main infectious agents for whom there are enough of evidences to be classified as human carcinogens: hepatitis B virus (HBV), hepatitis C virus (HCV), certain strains of the human Papilloma virus (HPV), *Helicobacter pylori* (*H. pylori*), Epstein-Barr virus (EBV), human immunodeficiency virus type 1 (HIV1), and human T-cell lymphotropic virus type I (HTLV1) and the Kaposi's sarcoma herpesvirus (KSHV) [12]. Except these well known agents there are others whose infection is associated to the development of the oncogenic process. In the study of Samaras et al. [13], they queried on many data bases articles based on a correlation between cancer and parasite/bacterial infections. They found for some agents including salmonella typhi (*S. Typhi*), *Opisthorchis viverrini*, *Clonorchis sinensis* and *Schistosoma hematobium*, high evidence of association between infection and cancer. It's noteworthy to highlight again that these infections are more frequent in developing countries. The association between infection and oncogenic process has two great implications: First, cancer appears in this point of view as potential transmitted disease. Secondly, known that there are efficient therapies or vaccines available for infectious diseases, cancer could then be prevented. For instance *H. pylori* infection is associated with a risk to develop gastric cancer. So, early eradication of this bacterium is associated with the decrease risk of gastric cancer in patient with gastric cancer [14]. Similarly vaccination against HPV, and HBV are respectively used to fight cervical cancer and hepatocellular carcinoma [15,16]. However the understanding of mechanisms paving the ways from infection to cancer remains to be clarified. Some oncogenic pathogens directly transform cell into tumour cells while others create an inflammatory and oxidative environment, promoting cancer development. These mechanisms include perversion of genome stability and cell cycle regulation, perturbation of the balance between oncogenes and tumour suppressors, creation of chronic inflammatory and oxidative environment. As result of these conditions created by infectious agent, resident cells will undergo mutations, cell proliferation,

resistance to cell death and angiogenesis.

2.1. Genome Instability

Many infectious agents in the course of the infection will affect the genome either by subverting host replication for their own replicative process, or by secreting substances able to affects genome integrity. Among all infectious agents, viruses have the first place as agents causing genome instability. Consistent with this the study of virus biology has been helpfull for the understanding of genome. When the virus is inside the host cells, the viral particle which is basically a molecule of DNA or RNA, could be integrate in host chromosome, in order to replicate viral particle and direct the expression of genes necessary for the formation of new viral particle. This integration is cause of insertion mutation including DNA rearrangement such as translocation, deletion, sequence duplication as well as, viral promoter-driven human transcription, viral-human transcript fusion, and DNA copy number alteration associated to cancer development [17]. The study of Paterlini-Bréchet et al [18], consistent with many other studies, highlights the high prevalence in human liver cancers of HBV-DNA integration in genes involved in cell signalling. In patients suffering from cervical cancer, Campitelli et al [19] report that mutational insertion constitutes a highly specific molecular marker of circulating tumor DNA in HPV-associated tumor patients. However All the microbes are not able to integrate host genome to induce genome instability, some could secrete genotoxic compounds able to directly induce DNA lesions or which can target protein responsible of the control of genome integrity. The bacterium *S. typhi* is the cause of typhoid fever which is very frequent in developing countries. Chronic *S. typhi* infection seems to be an important risk to develop carcinoma of gallbladder [20]. However except the metabolization of bile salt into carcinogenic compounds [21], *S. typhi* produces also genotoxic compounds including cytotoxic distending toxin B (CdtB) [22]. CdtB is a subunit of the virulence factor CDT producing by many bacteria. Once in the host cell, Cdt goes to the nucleus and breaks double-stranded DNA, resulting in the arrest of the cell cycle at the G2/M boundary [23].

2.2. Target of Cellular Oncogene or Tumor Suppressor by Infectious Protein

Infectious agents can produce proteins capable to affect the balance between tumour suppressor and oncogene. The infectious protein can achieve these actions by activating oncogene, while deactivating tumour suppressor or simply acting as normal cellular oncogene, thereby contributing to the oncogenic process. HPV infection illustrates clearly this, in fact the oncoproteins E7 and E5 of the human papilloma virus 16 bind and functionally inactivate tumor suppressor proteins p53 and Rb, respectively, and both disrupt the G1 arrest in response to DNA damages [24]. Viral or bacterial protein could be homologue of cellular protooncogene, or activate a cellular proto-oncogene. So the protein BHRF1 of

EBV virus is a homolog of the cellular anti-apoptotic Bcl-2 protein. Expression of BHRF1 in human B cells protects them from programmed cell death like the cellular Bcl-2 [25]. The Virulence factor cytotoxin associated gene A of *H. Pylori* (CagA), is known to be critical to many *H. Pylori* outcomes including gastric carcinoma. Cag A is directly injected in host cell by the bacterium, and once in the host cell can specifically and physically bind to many cellular proteins and modify their activity. For instance the Src homology 2 (SH2) domain containing phosphotyrosine phosphatase 2 (SHP-2) is the product of cellular oncogene PTPN11. Dysregulation or simply activation of SHP-2 is involved or found in the development of many malignancies including leukaemia and solid tumors [26]. CagA binds in phosphorylation-dependent manner to SHP-2 and thereby stimulates the phosphatase activity of SHP2 [27].

2.3. Infection and Inflammation Mediated Cancer

The infection mediated carcinogenesis, presented above relies on the ability of infectious agents or particles to enter into the host cells, however many microbes known as potential inducers of cancer are not able to enter into the host cell neither to produce proteins able to do that. They act by changing the cell environment. In fact one major mechanism of carcinogenesis is chronic inflammation, it's known as the 7th hallmark or cancer development [28]. Therefore, inflammation induced by infectious agent is one main mechanism of infection related cancer. For instance shistosomiasis induces chronic inflammation of the bladder, which seems to be associated with initiation of bladder cancer [29]. The presence of infectious agents in the body will trigger innate and acquired immunity, both associated with inflammatory response. The persistence of the infectious agent will then create a state of chronic inflammation. Generally infectious site is characterized by infiltrating immune cells; they will then produce pro-inflammatory cytokines, growth factors, and will release active oxygen species. Active oxygen species are most responsible for DNA damage and thus promote the initiation of the tumour [30]. Inflammatory cytokines will stimulate proliferation, escape to cell death, angiogenesis and acquisition of invasive phenotype. An illustration of this is *H. Pylori* infection, which induces chronic gastric inflammation, which is a route to cancer. In fact *Helicobacter gastritis* compared to others gastritis is characterized by high infiltration of mucosal levels of inflammatory cytokines, including IL-1 β , IL-6, IL-7, IL-8, IL-10 and TNF- α [31]. These cytokines are able then to modulate cell necrosis [32], affect the stability of the genome and modulate gene expression, cell growth and resistance to cell death. Accordingly, the chronic inflammatory response in HBV infected liver, gives rise to cirrhosis and hepatocarcinoma. In the study of Yu and colleague, IL-29, IL-8, and cyclooxygenase-2 were shown to be highly expressed in HBV infected patient or in HBV expressing cells [33]. Another mechanism featuring immune response related inflammation is the activation of the inflammasome. This response is activated when the cytosolic nucleotide-

binding and oligomerization domain (NOD)-like receptors (NLRs) recognize PAMPs in intracellular compartments. Inflammasome response consists in activation of caspase 1 by a platform of proteins, this caspase 1 will then induce the maturation of cytokines, including IL-1 β and IL-18 [34]. Inflammasome activation is undergoing by hepatic Macrophages following HCV infection, resulting in production of IL-1 β , whose action leads to liver inflammation [35]. IL-1 β , IL-18 and caspase 1 is found in the inflammatory environment associated to KSHV infection. During KSHV infection of endothelial cells, interferon gamma-inducible protein 16 (IFI16) interacts with the adaptor molecule ASC and procaspase-1 to form a functional inflammasome, which is responsible for the maturation and production of IL-1 β and IL-18. This could be a potential mechanism of inflammation associated lesion found in Kaposi's sarcoma [36, 37]. There are some evidences of possible association between *Mycoplasma hyorhinis* (*M. hyorhinis*) and the development of gastric and prostate cancers [38, 39]. Macrophages challenged with *M. hyorhinis*, underwent inflammasome activation and production of IL-1 β capable to promote gastric cancer cell migration and invasion [40]. The inflammatory process required implementation of specific intracellular mediators, including NF- κ B, Stat3, and mitogen-activated protein kinases JNK and p38. These proteins are crucial for the tumor development, regulating proliferation, cell death, migration, angiogenesis and invasion. The detailed mechanism related to each of these proteins is over the scope of this review, so we will focus only on NF- κ B and Stat3 for their high importance in inflammation related cancer. In fact their role in infection related inflammation and cancer is well documented, and they seem to be involved in major cases of infection induced inflammation related cancer, moreover, there are established synergistic crosstalk between the NF- κ B signalling and the Stat3 signalling in tumors [41-46].

Proteins NF- κ B is a family of transcription factors commonly expressed in almost all cell types and involved in immune response. NF- κ B signalling, is found in the cytoplasm sequestered by proteins I κ B, cytokine signalling will induce the degradation of I κ B in IKK dependent way. Proteins NF- κ B will then go into nucleus and trigger transactivation of many genes encoding for proteins regulating inflammation cell growth, cell proliferation, cell death, motility and angiogenesis [47-48]. NF- κ B is overexpressed in many cancers, and has a pivotal role linking inflammation to cancer [49]. Many observations illustrate the major and ubiquitous role of the protein NF- κ B in infection related cancer: *H. Pylori* infection on gastric epithelial cells induces NF- κ B activation [50]. NF- κ B is constitutively activated in Primary effusion lymphomas (PELs) associated with infection by KSHV [51]. The EBV latent membrane protein 1 (LMP1) is known to be sufficient to immortalize B cells. Expression of LMP1 in B cells induces NF- κ B activation and stimulates proliferation of these B cells. HTLV-I infection is causally associated with a variety of human diseases including leukemia/lymphoma. HTLV-I

triggers a persistent activation of NF- κ B, modifying the expression of a large array of host genes, participates as such to the initiation of T-cell transformation. The Tax protein encoded by HTLV-1 is an oncoprotein capable to immortalize human T cell and induces tumor in animal models [52, 53]. Tax is known to induce constitutive nuclear expression of NF- κ B, causing aberrant expression of cellular genes associated to the tumorigenesis [54, 55].

stat3 is a major mediator of the inflammatory response, its favours tumour cell proliferation, survival angiogenesis and suppress anti-tumour immunity [45, 46]. Activation of STAT3 occurs in many infection-related cancer including HPV-related cervical cancer, HCV and HBV-related hepatocarcinoma, Kaposi's Sarcoma [56-59]. For instance, In HPV-16 positive cervical cancer cell, Shukla et al.[56] found a correlation of constitutive active STAT3 with expression of HPV16 E6 and E7 oncoproteins and a negative association with levels of p53 and pRB. Activation of STAT3 is very rapid during the infection and is triggering by many cytokines and growth factors. For example following the infection of *S. typhi*, activation of STAT3 is observed in macrophages at 6h post infection [60]. Punjabi and co-worker [58], observed by infecting endothelial cells with KSHV a phosphorylation/activation of STAT3, and this activation persists as long as latent infection is maintained, giving as such the evidence that KSHV induced activation of STAT3 could be critical for pathogenesis of Kaposi's sarcoma. More insight were gaining by the work of Christine King [61], showing that activation of KSHV-induced activation of Stat3 required the phosphorylation/activation of STAT3 coupled with inactivation of TRIM28, a negative regulator of STAT3.

3. Plant Extracts as Therapeutic Potential in Infectious Diseases

The discovery of antibiotics has decreased the spread and severity of a wide variety of inferior diseases. However, and as a result of their uncontrolled use, the efficiency of many antibiotics is being threatened by the emergence of microbial resistance to existing chemotherapeutic agents [62]. While bioactive natural compounds have been isolated mainly from cultivable microbial strains, an untapped biologically active metabolites of different resources including plants remains to be investigated [63] to alleviate or help responding to current health care situations; such situations include but not limited to unmet clinical needs, increasing cost of chemotherapy, mycobacterial reemergence, and the emergence of antibiotic resistant microbial strains such as MRSA [64]. Microbial resistance occurs mainly in three general mechanisms: prevention of interaction of the drug with target; direct destruction or modification of the drug; and efflux of the drug from the cell [65]. These mechanisms were used by different microorganisms and led to the emergence of many pathogenic bacterial strains [64]. With pathogenic fungi, the situation is not so bright also, where Amphotericin B was for

many years the only treatment available for fungal infections. In late 1980s fluconazole and itraconazole was developed as additional therapeutic options [66]. Recently, azole derivatives are most widely used antifungal agents, although resistance for these drugs is emerging [67]. All the available antifungal drugs used to date are not ideal in efficiency, safety, and antifungal spectrum [68]. Combination antifungal therapy was also used to increase the efficiency but there is a real demand for a next generation of safer and more powerful antifungal agents [69]. Knowing that modifying known antimicrobial compounds is increasingly difficult created an urgent and very pressing need for isolation and identification of new bioactive chemicals from new sources including plants [70]. Plant derived natural products represent an attractive source of antimicrobial agents since they are natural, have manageable side effects and available at affordable prices [71]. Also plants derived agents may have different mechanisms than conventional drugs, and could be of clinical importance in health care improvement [72]. There are two main classes of plant derived agents. 1) phytoalexins which are low molecular weight compounds produced in response to microbial, herbivorous, or environmental stimuli [73]. Phytoalexins include simple phenylpropanoid derivatives, flavonoids, isoflavonoids, terpenes and polyketides [74]. 2) Phytoanticipins which are produced in plants before infection or from pre-existing compounds after infection [73]. Phytoanticipins include: glycosides, glucosinolates and saponins that are normally stored in the vacuoles of plant cells [75]. The antimicrobial potential of plant derived natural products is well documented. Schelz and colleagues reported the potential of menthol isolated from peppermint oil to eliminate the resistance plasmids of bacteria [76]. In another study carbazole alkaloids isolated from *Clausena anisata* stem bark showed high antibacterial and antifungal activities [77]. Thousands of other phytochemicals having in vitro antimicrobial activities were also screened. Such screening programs are essential for validating the traditional use of medicinal plants and for providing leads in the search for new antimicrobial agents [78]. A number of studies of the bioactivity of plant extracts have been conducted and many of these studies showed promising results in developing new biologically active agents. The methanolic extract of clove *Caryophyllus aromaticus* showed antibacterial activity against many bacterial genera and the highest activity was against *Staphylococcus aureus* [89]. Association of clove extract and antibiotics showed synergistic antibacterial activity against antibiotic resistant *Pseudomonas aeruginosa* [80]. Out of the 50 plants used in Indian traditional medicine, 72% showed antimicrobial activity including nine plants showed antifungal activity [81]. When some Palestinian plants were tested for bioactivity, out of fifteen used in traditional medicine, only eight showed antibacterial activity against eight different bacterial strains [82]. Butanol extracts of *Rosa damascene*, *Narcissus tazetta*, and *Inula viscosa* exhibited potent antimicrobial activities against different microorganism including Methicillin-resistant

Staphylococcus aureus and *Candida albicans* [83]. During the past decade there is an increase in the number of immunocompromised patients. This is probably due to the alteration of the immune system caused by human immunodeficiency virus (HIV), cancer chemotherapy, and organ and bone marrow transplantation in addition to the use of immune suppressors to treat many diseases [84]. The compromised immune system facilitates microbial infections including systemic mycosis. This leads to extensive use of Amphotericin B and azole derivatives as antifungal agents. Unfortunately, the wide range use of these antifungal agents leads to the emergence of drug resistant pathogenic fungi [84]. *Candida albicans* is opportunistic yeast that can cause vaginal, oral, and lung infections in addition to systemic tissue damage in AIDS patients [85]. This yeast was the target of many researchers to develop new antifungal agents. Out of twenty four medicinal plants used in traditional medicine in South Africa, two showed high potential to treat candidiasis [86]. Also some indigenous plants of Lebanon showed antimicrobial activity against *Candida albicans* and other tested microorganisms [87]. Successive isolation of antimicrobial compounds from plants depends upon the type of solvent used in extraction procedure [88]. Literature reported the use of different solvents to extract antimicrobial agents. The ethanol/methanol extracts of thirty four medicinal plants were more active than aqueous extracts against bacterial strains belonging to Enterobacteriaceae [88]. Methanolic extract of *Terminalia chebula* showed higher antibacterial potential compared with aqueous extract [71]. Mahasneh found that butanol extracts of several plants including: *Lotus halophilus*, *Pulicaria gnaphaloides*, *Capparis spinosa*, *Medicago laciniata*, *Limonium axillare* to exhibit superior antimicrobial activity compared with ethanol and aqueous extracts [89]. The ethanolic extract of 11 plant species from Argentina showed high antimicrobial activity against a list of microorganisms including methicillin, oxacillin, and gentamicin resistant *Staphylococcus* [90]. Of 16 plants studied, the methanolic and aqueous extracts of 10 Yemeni plants exhibited significant antimicrobial activity against three gram positive, two gram negative bacteria, and one fungus [91]. Jordanian plants were the focus of many researchers for their antimicrobial activities. Butanol, ethanol, petroleum ether, and aqueous extracts were prepared from nine Jordanian plants. Butanol extract showed superior antimicrobial activity compared with other extracts [92]. Of 27 ethanol extracts prepared from indigenous Jordanian plants, six plants showed promising antimicrobial activity against different test microorganisms [93]. In addition to their broad antimicrobial activities some Jordanian plants like *Sonchus oleraceus* and *Laurus nobilis* exhibited high antiquorum sensing activities [94]. Other Jordanian plants like *Crupina crupinastrum* and *Achillea biebersteinii* showed high antimicrobial activity against bacteria and fungi [95]. Additionally the methanolic extracts of two Jordanian plants *Artemisia herba-alba* and *Artemisia arborescens* showed high antibacterial activity against 32 isolates of *Mycoplasma* species [96].

4. Medicinal Plants Oxidative Stress Antioxidant and Cancer

Various active compounds (or their semi-synthetic derivatives) derived from medicinal plants have been assessed for their efficacy and tolerability in the treatment of breast cancer. Active oxygen may cause cancer through two possible mechanisms: gene mutations and the effects on signal transduction and transcription factors. Oxidative stress causes damages to DNA, phospholipids, proteins and carbohydrates on the cell membrane. Oxidation and injury to DNA induce genetic mutation. The presence of free radicals may enhance the mutation of some genes. An antioxidant is “any substance that delays, prevents or removes oxidative damage to a target molecule” [97]. Antioxidants can act by diverse mechanisms in the oxidative sequence. The human body complex antioxidant defense system consists of the dietary intake of antioxidants, as well as the endogenous production of antioxidative compounds, such as glutathione, etc. [98]. Antioxidants can be classified into a number of different groups as enzymatic and non enzymatic strategies. The enzymatic antioxidant involve superoxide dismutase, catalase, glutathione peroxidase and glutathione reductase, while non enzymatic antioxidants include the vitamins A, C, and E, glutathione, and lipoic acid, mixed carotenoids, several bioflavonoids, antioxidant minerals (copper, zinc, manganese, and selenium), etc. Antioxidants may work either alone, or in association with each other against different types of free radicals. Vitamin E inhibits the propagation of lipid peroxidation; the combination of vitamin C and vitamin E suppress the formation of hydroperoxide; metal complexing antioxidant such as penicillamine inhibit free radical formation in lipid peroxidation [99]. Human body is constantly generating free radicals, which causes oxidative stress. Factors such as drugs, pollution, immune responses to viruses, deficiency of natural antioxidants, ultraviolet rays and tobacco destroy the body potential of stabilizing free radicals. In addition to those exogenous sources, endogenous sources of oxidative stress include mitochondria, or microsomes and peroxisomes, and enzyme NADPH. The body has the power to neutralize them, but if there is an imbalance between the free radicals and the ability of the body to neutralize it, it causes oxidative stress. Oxidative stress may cause various problems and diseases such as diabetes, Alzheimer’s disease, Parkinson’s disease, aging and cancer. Oxidative stress causes Lipid peroxidation in cell membranes, determined as free radicals, reacting with polyunsaturated fatty acids. Cell membranes contain polyunsaturated fatty acids (PUFAs) and lowdensity lipoproteins (LDL). They are sensitive to free radicals [100]. The interaction of ROS and lipids consists of three different steps: initiation, propagation and termination. The molecular oxygen reacts with carbon-centered free radicals, and thus, lipid hydroperoxides (LOOH) are formed. LOOH alter the membrane structure and function. Free radicals cause proteins oxidation. There are various markers of protein oxidation, which include protein carbonyl derivatives, oxidized

amino acid side chains and formation of advanced glycation end products. In the oxidation process, Protein carbonyl derivatives are formed early, and are generated as the peptide main chain as some amino acid side chains that are cleaved (arginine, lysine, or threonine), are oxidized [101-103]. The carbonyl groups are relatively stable [103], and may result in loss of protein function, as well as increased degradation of soluble proteins [101]. Protein oxidation has also been shown to be a chain reaction and may be inhibited by chain-breaking antioxidants [104]. Oxidation of proteins may develop some problem, but protein damage can be repaired, and is a non-lethal event for the cell [105]. DNA is especially sensitive to damage due to its potential to create cumulative mutations, which may disrupt cellular homeostasis [106]. DNA may be damaged by ROS and cause permanent structural changes in, as base-pair mutations, deletions, insertions, rearrangements and sequence amplification [107]. Continuous oxidative damage to DNA may lead to alterations in signaling cascades or gene expression, and may cause replication errors and genomic instability [106]. In recent years, oxidative stress and the mechanisms by which cancer is caused has been extensively studied. Cancer development is a multistage process which involves mutations in critical genes required for maintenance of the cellular homeostasis [106]. Oxidative stress causes initiation, promotion and progression of carcinogenesis [108]. ROS play an important role in the development of cancer. Oxidative damage to DNA or of antioxidant defense systems leads to mutation, activated transcription factors, modification of gene expression and chromosomal aberrations, processes which have been described as the agents of progressions of cancer. Inflammation also causes DNA mutation [109]. 25% of all cancers in the world is due to chronic inflammation due to infection or injury [110]. Various chemicals such as chlorinated compounds, metal ions, aromatic hydrocarbons and some peroxisome proliferators have been shown to induce oxidative stress, which damages the DNA. They may, therefore, partly account for the development, especially of workrelated cancers. Many cancers are associated with increased production of ROS [108]. Natural products, especially plants, have been used for the treatment of various diseases from ancient times. People of Egypt, China, India and Greece have been using terrestrial plants as medicines, and a large number of modern drugs have been developed from them. Medicinal plants have been used in the treatment of many diseases, such as diabetes, obesity and cancer, etc. There are many evidences that the generation of free radicals inside the body cause damages to DNA and lead to the development of cancer, etc., and if these free radicals are neutralized by the antioxidants from different medicinal plants, then it prevents cancer. Several studies have shown that plant derived antioxidant scavenge free radicals and modulate oxidative stress. Free radicals are the cause of many diseases such as cancer, atherosclerosis, diabetes, neurodegenerative disorders and aging; different experimental and clinical studies have proved that higher intake of antioxidant rich food is associated with decreased

risk of cardiovascular diseases and cancer. The free radical neutralizing property of several plants have been screened by various researchers. Plants have been used in the treatment of cancer. The National Cancer Institute collected about 35,000 plant samples from 20 different countries, and has screened around 114,000 extracts for anticancer activity. 60% of the commercially available anticancer drugs are from natural sources. Treatment by herbal medicines may have some advantages over treatment by single purified chemicals [111]; as hebal medicine are the mixtures of more therapeutic or preventive components, and so might have more activity than single products alone. The antioxidant and anti-tumor effects of extracts from various herbs and medicinal plants have been proved experimentally and clinically. Several in vitro or in vivo studies have proved the anticancer potential of the extracts from several medicinal plants [112-114]. Experimental studies of aqueous extracts from willow (*Salix* sp.) leaves show prevention of proliferation of cancer cells [114]. *Ganoderma lucidum* methanolic extracts induced apoptosis in human breast cancer cells Hu et al. [113] and Kao et al. [115] studied that an aqueous extract of Bu-Zhong-Yi-Qi-Tang (a mixture of ten herbs), had the ability to induce apoptosis in hepatoma cells. Most of the plants contain phenolic and flavonoid compounds, which have antioxidant activities, and thus, prevent oxidative stress and cancer [116]. The effect of an aqueous extract of *Paeoniae lactiflora* were studied on HepG2 and Hep3B hepatoma cells, which showed apoptosis. Yano et al. [117] stated that aqueous extract of Sho-Saiko-To caused inhibition of the proliferation of KIM-1 human hepatoma cells. It was stated by Bonham et al. [112] that PE-SPES (mixture of eight herbs) had been used as a clinical treatment of prostate cancer. Chemical and diferent studies of various extracts from the herbs were found to be useful in preventing radiation damages and purify blood quality [118,119]. The seeds of *Luffa aegyptiaca* has the ability to destroy the human metastatic melanoma [120].

5. Medicinal Plants in Clinical Use

The anticancer agents, vinblastine and vincristine from the Madagascar periwinkle, *Catharanthus roseus* G. Don. (Apocynaceae), introduced a new era of the use of plant material as a medication for treatment. They were the first agents to advance into clinical use for the treatment of cancer. Vinblastine and vincristine are used in combination with other cancer drugs, for the treatment of various kinds of cancers, including leukemias, lymphomas, advanced testicular cancer, breast and lung cancers The isolation of paclitaxel (Taxol[®], 3) from the bark of the Pacific Yew, *Taxus brevifolia* Nutt. (Taxaceae), is another good step in the discovery of natural product drug. Various parts of *Taxus brevifolia* and other *Taxus* species (e.g., *Taxus Canadensis* Marshall, *Taxus baccata* L.) have been used by several native American tribes for the treatment of various diseases, while *Taxus baccata* was reported to use in India as a medicine for the treatment of cancer. The paclitaxel was clinically introduced to the US market in the early 1990s. Paclitaxel is

active against a number of cancer types, for example: ovarian cancer, advanced breast cancer, small and non-small cell lung cancer. Camptothecin was isolated from the Chinese ornamental tree, *Camptotheca acuminata* Decne (Nyssaceae), the clinical trials in the 1970s dropped it because of severe bladder toxicity. Derivatives of camptothecin, Topotecan and irinotecan, are used for the treatment of ovarian and small cell lung cancers, and colon cancers, respectively.

6. Conclusions

The potential isolation and use of new and novel bioactive products from plant origins is still very productive playground for the development of new drugs to improve health care in certain medical fields. Free radicals are the cause of oxidative stress, which may causes injury to cells, gene mutation, and may lead to cancer. Oxidative stress causes cancer, by the interaction with intracellular signal transduction and transcription factors, directly or indirectly. Medicinal plants are main sources in healing of the cancer around the world. This property of the plants is because of the presence of potent anti cancer substances. Medical plants treatment of cancer is prevalent, especially in our country where resources are limited. Several medicinal plants have been known to cure and control cancer. Most of the medications used word wise contains herbal product, with no side effects. It is essential to emphasize that extensive in vitro and in vivo tests must be conducted to assure the selection of active and nontoxic anticancer and antimicrobial phytochemicals.

Authorship Contribution

All authors contributed to the design, preparation, editing, and final review of the manuscript.

Acknowledgments

Authors thank the collaborators of their respective institutions for the comments on the manuscript.

References

- [1] T. SIBANDA, A.I. OKOH. In vitro evaluation of the interactions between acetone extracts of *Garcinia kola* seeds and some antibiotics; *Afr. J. Biotech.*, 7(2008b), pp. 1672-1678.
- [2] D.O. Ochwang'i, C.N. Kimwele, J.A. Oduma, P.K. Gathumbi, J. M. Mbaria, S.G. Kiama. Medicinal plants used in treatment and management of cancer in Kakamega County, Kenya. *J Ethnopharmacol.*, 151(2014), pp. 1040-1055.
- [3] T. Rabe, J. van Staden. Antibacterial activity of South African plants used for medicinal purposes. *J Ethnopharmacol.*, 56(1997), pp. 81-7.
- [4] P. Pillay, V.J. Maharaj, P.J. Smith. Investigating South African plants as a source of new antimalarial drugs. *Journal of Ethnopharmacology*. 119(2008), pp. 438-454.
- [5] H. Lai, N.P. Singh. Oral artemisinin prevents and delays the development of 7, 12-dimethylbenz[a]anthracene (DMBA)-induced breast cancer in the rat. *Cancer Lett.*, 231(2006), pp. 43-48.
- [6] J. Sun, Y.F. Chu, X.Z. Wu, R.H. Liu. Antioxidant and anti-proliferative activities of fruits. *Journal of Agricultural and Food Chemistry*. 50 (2002), pp. 7449-7454.
- [7] C. De Martel, J. Ferlay, S. Franceschi, J. Vignat, F. Bray, D. Forman, M. Plummer. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. *Lancet Oncol* 13 (2012), pp. 607–615.
- [8] J.V. Remais, G. Zeng, G. Li, L. Tian, and M. M. Engelgau. Convergence of non-communicable and infectious diseases in low- and middle-income countries. *International Journal of Epidemiology* 42(2012), pp. 221–227.
- [9] A. Jemal, F. Bray, D. Forman, M. O'Brien, J. Ferlay, M. Center, D. M. Parkin, D. M. Parkin. The global health burden of infection associated cancers in the year 2002. *Int. J. Cancer* 118(2006), pp.3030–3044.
- [10] A. Rahbar, A. Orrego, I. Peredo, M. Dzabic, N. Wolmer-Solberg, K. Strååt, G. Stragliotto, C. Söderberg-Nauclér. Human cytomegalovirus infection levels in glioblastoma multiforme are of prognostic value for survival. *J Clin Virol*. 57(2013), pp.36-42.
- [11] C. Söderberg-Nauclér, A. Rahbar, G. Stragliotto. Survival in Patients with Glioblastoma Receiving Valganciclovir. *N Engl J Med*. 369(2013), pp. 985-986.
- [12] N. E. Mueller. Cancers Caused by Infections Unequal Burdens. *Cancer Epidemiol Biomarkers Prev* March 12(2003), 237s.
- [13] V. Samaras, P. I. Rafailidis, E. G. Mourtzoukou, G. Peppas, M. E. Falagas. Chronic bacterial and parasitic infections and cancer: a review. *J Infect Dev Ctries*. 4(2010), pp. 267-281.
- [14] C. Y. Wu, K. N. Kuo, M. S. Wu, Y. J. Chen, C. B. Wang, J. T. Lin. (2009). Early *Helicobacter pylori* eradication decreases risk of gastric cancer in patient with peptic ulcer disease. *Gastroenterology*. 137(2009), pp. 1641-8.
- [15] D. Saslow, P. E. Castle, J. T. Cox, D. D. Davey, M. H. Einstein, D. G. Ferris, S. J. Goldie et al. American Cancer Society Guideline for Human Papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. *CA Cancer J Clin*. 57(2007), pp. 7–28.
- [16] M-H. Chang, T. H-H. Chen, H-M. Hsu, T-C. Wu, M-S. Kong, D-C. Liang, Y-H Ni, C-J. Chen, D-S. Chen. Prevention of Hepatocellular Carcinoma by Universal Vaccination against Hepatitis B Virus: The Effect and Problems. *Clin Cancer Res*. 11(2005), pp.7953-7.
- [17] Z. Jiang, S. Jhunhunwala, J. Liu, P. M. Haverty, M. I. Kennemer, Y. Guan, W. Lee, P. Carnevali et al. The effects of hepatitis B virus integration into the genomes of hepatocellular carcinoma patients. *Genome Res*. 22(2012), pp. 593–601.
- [18] P. Paterlini-Bréchet, K. Saigo, Y. Murakami, M. Chami, D. Gozuacik, C. Mugnier, D. Lagorce and C. Bréchet. Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene. *Oncogene* 22 (2003), pp. 3911–3916.

- [19] M. Campitelli, E. Jeannot, M. Peter, E. Lappartient, S. Saada, et al. Human Papillomavirus Mutational Insertion: Specific Marker of Circulating Tumor DNA in Cervical Cancer Patients. *PLoS ONE* 7(2012): e43393. doi:10.1371/journal.pone.0043393
- [20] U. Dutta, P.K. Garg, R. Kumar, R.K. Tandon. Typhoid carriers among patients with gallstones are at increased risk for carcinoma of the gallbladder. *Am J Gastroenterol.* 95 (2000), pp.784-7.
- [21] A. I. Prieto, F. Ramos-Morales and J. Casadesús. Bile-induced DNA damage in *Salmonella enterica*. *Genetics* 168 (2004), pp.1787-1794.
- [22] E. Haghjoo, J.E. Galán. *Salmonella typhi* encodes a functional cytolethal distending toxin that is delivered into host cells by a bacterial-internalization pathway. *Proc Natl Acad Sci U S A.* 101(2004), pp. 4614-9.
- [23] W. Heywood, B. Henderson, and S. P. Nair. Cytolethal distending toxin: creating a gap in the cell cycle. *J. Med. Microbiol.* 54(2005), pp.207-216.
- [24] P. A. Havre, J. Yuan, L. Hedrick L, et al. p53 inactivation by HPV 16 E6 results in increased mutagenesis in human cells. *Cancer Research*, 55(1995): 4420-4.
- [25] S. Henderson, D. Huen, M Rowe, C. Dawson, G. Johnson, A. Rickinson. Epstein-Barr virus-coded BHRF1 protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death. *Proc. Natl. Acad. Sci.* 90(1993), pp. 8479–8483.
- [26] M. G. Mohi and B.G. Neel. The role of Shp2 (PTPN11) in cancer. *Curr Opin Genet Dev.* 17(2012), pp. 23-30.
- [27] H. Higashi, R Tsutsumi, S. Muto, T. Sugiyama, T. Azuma, M. Asaka, M. Hatakeyama. SHP-2 tyrosine phosphatase as an intracellular target of *Helicobacter pylori* CagA protein. *Science.* 295(2002), pp. 683-6.
- [28] A. Mantovani. Cancer: inflamming metastasis. *Nature* 457(2009), pp. 36–7.
- [29] M. P. Rosin, S. S. El-Din, J. A. Ward, W.A Anwar. Involvement of inflammatory reactions and elevated cell proliferation in the development of bladder cancer in schistosomiasis patients. *Mutat. Res.*305 (1994), pp. 283–292.
- [30] H. Wiseman and B. Halliwell. Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer *Biochem. J.* 313 (1996), pp. 17–29.
- [31] Acacia Lamb and Lin-Feng Chen. Role of the *Helicobacter pylori*-induced inflammatory response in the development of gastric cancer. *Journal of Cellular Biochemistry* 114 (2013), pp. 491–497.
- [32] M. Roulis, M. Armaka, M. Manoloukos, M. Apostolaki, G. Kollias. Intestinal epithelial cells as producers but not targets of chronic TNF suffice to cause murine Crohn-like pathology. *Proc Natl Acad Sci U S A.* 108(2011), pp. 5396-401.
- [33] Y. Yu, R. Gong, Y. Mu, Y. Chen, C. Zhu, Z. Sun, M. Chen, Y. Liu, Y. Zhu, J. Wu. Hepatitis B virus induces a novel inflammation network involving three inflammatory factors, IL-29, IL-8, and cyclooxygenase-2. *J Immunol* 187(2011), pp. 4844-60.
- [34] M. Lamkanfi, T-D. Kanneganti, L. Franchi and G. Núñez. Caspase-1 inflammasomes in infection and inflammation. *Journal of Leukocyte Biology* 82 (2007), pp. 2 220-225.
- [35] A. A. Negash, H. J. Ramos, N. Crochet, D. T. Lau, B. Doehle, N. Papic, D. A. Delker et al. IL-1 β Production through the NLRP3 Inflammasome by Hepatic Macrophages Links Hepatitis C Virus Infection with Liver Inflammation and Disease. *PLOS Pathogens* 9(2013),| e1003330
- [36] V. Singh, N. Kerur, V. Bottero, S. Dutta, S Chakraborty, M. Ansari, N. Paudel, L. Chikoti, B. Chandran. Kaposi's sarcoma-associated herpesvirus latency in endothelial and B cells activates gamma interferon-inducible protein 16-mediated inflammasomes. *J Virol.* 87(2013), pp.4417-31.
- [37] N. Kerur, M. V. Veettil, N. Sharma-Walia, V. Bottero, S. Sadagopan, P. Otageri and Bala Chandran. IFI16 Acts as a Nuclear Pathogen Sensor to Induce the Inflammasome in Response to Kaposi Sarcoma-Associated Herpesvirus Infection. *Cell Host & Microbe* 9 (2011), pp. 363–375.
- [38] S. Huang, J. Y. Li, J. Wu, L. Meng, C.C. Shou. Mycoplasma infections and different human carcinomas. *World J Gastroenterol* 7(2011), pp. 266–269.
- [39] C. Urbanek, S. Goodison, M. Chang, S. Porvasnik, N. Sakamoto et al. Detection of antibodies directed at M. hyorhinis p37 in the serum of men with newly diagnosed prostate cancer. *BMC Cancer* 11 (2011): 233.
- [40] Y. Xu, H. Li, W. Chen, X. Yao, Y. Xing, et al. Mycoplasma hyorhinis Activates the NLRP3 Inflammasome and Promotes Migration and Invasion of Gastric Cancer Cells. *PLoS ONE* 8(2011): e77955. doi:10.1371/journal.pone.0077955.
- [41] L. M. Hix, J. Karavitis, M. W. Khan, Y.H. Shi, K Khazaie, M. Zhang. Tumor STAT1 transcription factor activity enhances breast tumor growth and immune suppression mediated by myeloid-derived suppressor cells. *J Biol Chem.* 288 (2013), pp. 1676-88.
- [42] J.A. DiDonato, F. Mercurio, M. Karin. NF- κ B and the link between inflammation and cancer. *Immunol Rev.* 246 (2012), pp. 379-400.
- [43] F. E. Wagner and Á. R. Nebreda. Signal integration by JNK and p38 MAPK pathways in cancer development. *Nature Reviews Cancer* 9 (2009), pp. 537-549.
- [44] C.Y. Fang, C.H. Lee, C.C Wu, Y. T. Chang, S. L. Yu, S. P. Chou, P.T. Huang, C.L. Chen, J. W. Hou, Y. Chang, C. H. Tsai, K. Takada, J.Y. Chen. Recurrent chemical reactivations of EBV promotes genome instability and enhances tumor progression of nasopharyngeal carcinoma cells. *Int J Cancer.* 124(2009), pp. 2016-25.
- [45] H. Yu, D. Pardoll and R. Jove. STATs in cancer inflammation and immunity: a leading role for STAT3. *Nature Reviews Cancer* 9 (2009), pp. 798-809.
- [46] G. Niu, K. L. Wright, M. Huang, L. Song, E. Haura, J. Turkson, S. Zhang et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. *Oncogene* 21 (2002), pp. 2000- 2008.
- [47] T-X. Xie, N. Zhang, W. Gong, S. Huang. Constitutive NF-kappaB activity regulates the expression of VEGF and IL-8 and tumor angiogenesis of human glioblastoma. *Oncol Rep.* 23(2010), pp.725–732.
- [48] B. B. Aggarwal. Nuclear factor- κ B: The enemy within. *Cancer Cell*, 6(2004), pp. 3.

- [49] Ben-Neriah Y.M. Karin. Inflammation meets cancer, with NF- κ B as the matchmaker. *Nat Immunol.* 12 (2011), pp. 715-723.
- [50] S. Maeda, H. Yoshida, K. Ogura, Y. Mitsuno, Y. Hirata, Y. Yamaji, M. Akanuma, Y. Shiratori, M. Omata. H. pylori activates NF-kappaB through a signaling pathway involving IkappaB kinases, NF-kappaB-inducing kinase, TRAF2, and TRAF6 in gastric cancer cells. *Gastroenterology*, 119(2000), pp. 97-108.
- [51] S. A. Keller, E.J. Schattner and E. Cesarman. Inhibition of NF- κ B induces apoptosis of KSHV-infected primary effusion lymphoma cells. *Blood* 96 (2000), pp. 2537–254.
- [52] N. Benvenisty, D.M. Ornitz, G.L. Bennett, et al. Brain tumours and lymphomas in transgenic mice that carry HTLV-I LTR/c-myc and Ig/tax genes. *Oncogene*. 7(1992), pp. 2399-2405.
- [53] R. Grassmann, S. Berchtold, I. Radant, M. Alt, B. Fleckenstein, J. G. Sodroski, W. A. Haseltine and U. Ramstedt. Role of human T-cell leukemia virus type 1 X region proteins in immortalization of primary human lymphocytes in culture. *J. Virol.* 66 (1992), pp. 74570-4575.
- [54] S-C. Sun and S. Yamaoka. Activation of NF- κ B by HTLV-I and Implications for cell transformation *Oncogene* 24(2005), pp. 5952–5964.
- [55] T. Portis, J.C. Harding, L. Ratner. The contribution of NF-kappa B activity to spontaneous proliferation and resistance to apoptosis in human T-cell leukemia virus type 1 Tax-induced tumors. *Blood*. 98(2001), pp.1200-1208.
- [56] J. Teng, X. Wang, Z. Xu and N. Tang. HBx-dependent activation of twist mediates STAT3 control of epithelium-mesenchymal transition of liver cells. *Journal of Cellular Biochemistry*. 114, (2013), pp. 1097–1104.
- [57] S. Shukla, G. Shishodia, S. Mahata, S. Hedau, A. Pandey, S. Bhambhani, S. Batra, S. F. Basir et al. Aberrant expression and constitutive activation of STAT3 in cervical carcinogenesis: implications in high-risk human papillomavirus infection. *Molecular Cancer* 9(2010), pp. 282.
- [58] S. A. Punjabi, P. A. Carroll, L. Chen, and M. Lagunoff. Persistent Activation of STAT3 by Latent Kaposi's Sarcoma-Associated Herpesvirus Infection of Endothelial Cells. *J Virol*. 81(2007), pp. 2449–2458.
- [59] G. Waris, J. Turkson, T. Hassanein, A. Siddiqui. Hepatitis C virus (HCV) constitutively activates STAT-3 via oxidative stress: role of STAT-3 in HCV replication. *J Virol*. 79(2005), pp. 1569-80.
- [60] T. Lin and K. Bost. STAT3 activation in macrophages following infection with Salmonella. *Biochem Biophys Res Commun*. 321 (2004), pp. 828–834.
- [61] C. A. King. Kaposi's Sarcoma-Associated Herpesvirus Kaposin B induces unique mono-phosphorylation of STAT3 at serine 727 and MK2-mediated inactivation of the STAT3 transcriptional repressor, TRIM28. *J. Virol.* 87(2013), pp. 15 8779-8791.
- [62] Cowan, M. (1999), Plant products as antimicrobial agents. *Clinical Microbiology Reviews*, 12, 564–582.
- [63] Quiroga, E., Sampietro, A. & Vattuone, A. (2001). Screening antifungal activities of selected medicinal plants, *Journal of Ethnopharmacology*, 74, 89-96.
- [64] Alanis, L. (2005) Resistance to antibiotics: are we in the post-antibiotic era?. *Archives in Medical Research*, 36, 697–705.
- [65] Alviano, D. & Alviano, A. (2009). Plant extracts: search for new alternative to treat microbial diseases. *Current Pharmaceutical Biotechnology*, 10, 106-121.
- [66] Ficker, E., Arnason, T., Vindas, S., Alvarez, P., Akpagana, K., & Gbeassor, M. (2005). Inhibition of human pathogenic fungi by ethnobotanically selected plant extracts. *Mycoses*, 46, 29–37.
- [67] Groll, A., Piscitelli, S., & Walsh, T. (1998). Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. *Advances in Pharmacology*, 44, 343–500.
- [68] Di Domenico, B. (1999). Novel antifungal drugs. *Current Opinion in Microbiology*, 2, 509- 515.
- [69] Bartoli J., Turmo, E., Alguero, M., Boncompte, E., Vericat, M., Conte, L., Ramis, J., Merlos, M., Garcia-Rafanell, J. & Forn, J. (1998). New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinone derivatives of 3-amino-2-aryl-1-azoly-2-butanol. *Journal of Medicinal Chemistry*, 41, 1869-1882.
- [70] Barker, J. (2006). Antibacterial drug discovery and structure-based design. *Drug Discovery Today*, 11, 391-404
- [71] Ghosh, A., Das, B., Roy, A., Mandal, B. & Chandra, G. (2008). Antibacterial activity of some medicinal plant extracts. *Journal of Natural Medicines*, 62, 259–262.
- [72] Eloff, J. (1998). Which extractant should be used for the screening and isolation of antimicrobial components from plants?, *Journal of Ethnopharmacology*, 60, 1–8.
- [73] Van Etten, H., Mansfield, W., Bailey, J. & Farmer, E. (1994). Two classes of plant antibiotics: phytoalexins versus phytoanticipins. *Plant Cell*, 6, 1191-1192.
- [74] Grayer, R. & Harborne, J. (1994). A survey of antifungal compounds from plants, 1982-1993. *Phytochemistry*, 37, 19-42.
- [75] Osbourn, A. (1996). Preformed antimicrobial compounds and plant defense against fungal attack. *The Plant Cell*, 8, 1821-1831.
- [76] Schelz, Z., Molnar, J., & Hohmann, J. (2006). Antimicrobial and antiplasmid activities of essential oils, *Fitoterapia*, 77(4):279-285.
- [77] Chakrabarty, M. (2003). Microorganisms and cancer: quest for therapy. *Journal of Bacteriology*, 185 (9), 2683-2686.
- [78] Alviano, D. & Alviano, A. (2009). Plant extracts: search for new alternative to treat microbial diseases. *Current Pharmaceutical Biotechnology*, 10, 106-121.
- [79] Ushimaru, P., da Silva, M., Di Stasi, L., Barbosa, L. & Junior, A. (2007). Antibacterial activity of medicinal plant extracts, *Brazilian Journal of Microbiology*, 38:717-719.
- [80] Nascimento F., Gilsen, J., Paulo, F. & Giuliana, S. (2000). Antibacterial activity of plant extracts and phytochemicals on antibiotic-resistant bacteria. *Brazilian Journal of Microbiology*, 31, 247-256.
- [81] Srinivasan, D., Sangeetha, N., Suresh, T. & Perumalsamy, P. (2001). Antimicrobial activity of certain Indian medicinal plants used in folkloric medicine. *Journal of Ethnopharmacology*, 74, 217-220.

- [82] Essawi, T. & Srour, M. (2000). Screening of some Palestinian medicinal plants for antibacterial activity, *Journal of Ethnopharmacology*, 70, 343-349.
- [83] Talib, W. & Mahasneh, A. (2010b). Antimicrobial, Cytotoxicity and Phytochemical Screening of Jordanian Plants Used in Traditional Medicine. *Molecules*, 15, 1811-1824.
- [84] Alexander, B. & Perfect, J. (1997). Antifungal resistance trends toward the year 2000, implication for therapy and new approaches. *Drugs*, 54, 657-678.
- [85] Madigan, T., Martinko, J., & Parker, J. (2006). *Biology of Microorganisms* (eleventh Edition), Pearson, USA.
- [86] Motsei, M., Lindsey, J., van Staden & Jager, A. (2003). Screening of Traditionally used South African Plants for Antifungal Activity against *Candida albicans*. *Journal of Ethnopharmacology*, (86), 235-241.
- [87] Barbour, K., Al Sharif, M., Sagherian V., Habre, A., Talhouk, R. & Talhouk, S. (2004). Screening of selected indigenous plants of Lebanon for antimicrobial activity. *Journal of Ethnopharmacology*, 93, 1-7.
- [88] Pareke, J. & Chanda, S. (2007). In vitro screening of antibacterial activity of aqueous and alcoholic extracts of various Indian plant species against selected pathogens from Enterobacteriaceae. *African Journal of Microbiology Research*, 6, 92-99.
- [89] Mahasneh, A. (2002). Screening of some indigenous Qatari medicinal plants for antimicrobial activity. *Phytotherapy Research*, 16(8), 751-3.
- [90] Zampini, I., Cuello, S., Alberto, M., Ordoñez, R., Almeida, R., Solorzano, E. & Isla, M. (2009). Antimicrobial activity of selected plant species from "the Argentine Puna" against sensitive and multi-resistant bacteria. *Journal of Ethnopharmacology*, 124(3):499-505.
- [91] Mothana, R., Lindequist, U., Gruenert, R., & Bednarski, P. (2009). Studies of the in vitro anticancer, antimicrobial and antioxidant potentials of selected Yemeni medicinal plants from the island Soqatra. *BMC Complementary and Alternative Medicine*, 9, record number 7.
- [92] Mahasneh, A. & El-Oqlah, A. (1999). Antimicrobial activity of extracts of herbal plants used in the traditional medicine in Jordan. *Journal of Ethnopharmacology*, 64, 271- 276.
- [93] Al-Bakri, A. & Afifi, F. (2007). Evaluation of antimicrobial activity of selected plant extracts by rapid XTT colorimetry and bacterial enumeration. *Journal of Microbiological Methods*, 68 (1), 19-25.
- [94] AL-Hussaini, R. & Mahasneh A. (2009). Microbial growth and quorum sensing antagonist activities of herbal plant extracts. *Molecules*, 14, 3425-3435.
- [95] Khalil, A., Dababneh, B., & Al-Gabbiesh, A. (2009). Antimicrobial activity against pathogenic microorganisms by extracts from herbal Jordanian plants. *Journal of Food, Agriculture and Environment*, 7 (2), 103-106.
- [96] Al-Momani, W., Abu-Basha, E., Janakat, Nicholas, R. & Ayling (2007). In vitro antimycoplasmal activity of six Jordanian medicinal plants against three *Mycoplasma* species. *Tropical Animal Health and Production*, 39, (7), 515-519.
- [97] Halliwell B, Gutteridge J (2007) Free radicals in biology and medicine. (4th Edn), Oxford University Press, Oxford, USA.
- [98] Clarkson PM, Thompson HS (2000) Antioxidants: what role do they play in physical activity and health? *Am J Clin Nutr* 72: 637S-646S.
- [99] Feher J, Csomos G, Vereckei A (1987) Free radical reactions in medicine. Springer-Verlag, Berlin-Heidelberg, USA 40-43.
- [100] de Zwart LL, Meerman JH, Commandeur JN, Vermeulen NP (1999) Biomarkers of free radical damage applications in experimental animals and in humans. *Free Radic Biol Med* 26: 202-226.
- [101] Berlett BS, Stadtman ER (1997) Protein oxidation in aging, disease, and oxidative stress. *J Biol Chem* 272: 20313-20316.
- [102] Dean RT, Fu S, Stocker R, Davies MJ (1997) Biochemistry and pathology of radical-mediated protein oxidation. *Biochem J* 324 : 1-18.
- [103] Morabito MA, Sheng M, Tsai LH (2004) Cyclin-dependent kinase 5 phosphorylates the N-terminal domain of the postsynaptic density protein PSD-95 in neurons. *J Neurosci* 24: 865-876.
- [104] Benderitter M, Maupoil V, Vergely C, Dalloz F, Briot F, et al. (1998) Studies by electron paramagnetic resonance of the importance of iron in the hydroxyl scavenging properties of ascorbic acid in plasma: effects of iron chelators. *Fundam Clin Pharmacol* 12: 510-516.
- [105] Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, et al. (2007) Free radicals and antioxidants in normal physiological functions and human disease. *Int J Biochem Cell Biol* 7 : 44-84.
- [106] Powell JM, McCrory DF, Jackson-Smith DB, Saam H (2005) Manure collection and distribution on Wisconsin dairy farms. *J Environ Qual* 34: 2036-2044.
- [107] Cerutti PA (1994) Oxy-radicals and cancer. *Lancet* 344: 862-863.
- [108] Cook PLM, Wenzhöfer F, Rysgaard S, Galaktionov OS, Meysman FJR, et al. (2006) Quantification of denitrification in permeable sediments: Insights from a two dimensional simulation analysis and experimental data. *Limnol Oceanogr Methods* 4: 294-307.
- [109] Cook A, Blaustein M, Spinazzola J, van der Kolk B (2003) Complex trauma in children and adolescents. National Child Traumatic Stress Network, Complex Trauma Taskforce.
- [110] Coussens LM, Werb Z (2002) Inflammation and cancer. *Nature* 420: 860-867.
- [111] Vickers A (2002) Botanical medicines for the treatment of cancer: rationale, overview of current data, and methodological considerations for phase I and II trials. *Cancer Invest* 20: 1069-1079.
- [112] Bonham M, Arnold H, Montgomery B, Nelson PS (2002) Molecular effects of the herbal compound PC-SPES: identification of activity pathways in prostate carcinoma. *Cancer Res* 62: 3920-3924.
- [113] Hu H, Ahn NS, Yang X, Lee YS, Kang KS (2002) Ganoderma lucidum extract induces cell cycle arrest and apoptosis in MCF-7 human breast cancer cell. *Int J Cancer* 102: 250-253.
- [114] El-Shemy HA, Aboul-Enein AM, Aboul-Enein MI, Issa SI, Fujita K (2003) The effect of willow leaf extracts on human leukemic cells in vitro. *J Biochem Mol Biol* 36: 387-389.

- [115] Kao ST, Yeh CC, Hsieh CC, Yang MD, Lee MR, et al. (2001) The Chinese medicine Bu-Zhong-Yi-Qi-Tang inhibited proliferation of hepatoma cell lines by inducing apoptosis via G0/G1 arrest. *Life Sci* 69: 1485-1496.
- [116] Meyers KJ, Watkins CB, Pritts MP, Liu RH (2003) Antioxidant and antiproliferative activities of strawberries. *J Agric Food Chem* 51: 6887-6892.
- [117] Yano H, Mizoguchi A, Fukuda K, Haramaki M, Ogasawara S, et al. (1994) The herbal medicine sho-saiko-to inhibits proliferation of cancer cell lines by inducing apoptosis and arrest at the G0/G1 phase. *Cancer Res* 54: 448-454.
- [118] Wang X, Wei L, Ouyang JP, Muller S, Gentils M, et al. (2001) Effects of an angelica extract on human erythrocyte aggregation, deformation and osmotic fragility. *Clin Hemorheol Microcirc* 24: 201-205.
- [119] Xie F, Li X, Sun K, Chu Y, Cao H, et al. (2001) An experimental study on drugs for improving blood circulation and removing blood stasis in treating mild chronic hepatic damage. *J Tradit Chin Med* 21: 225-231.
- [120] Poma A, Miranda M, Spanò L (1998) Differential response of human melanoma and Ehrlich ascites cells in vitro to the ribosome-inactivating protein luffin. *Melanoma Res* 8: 465-467.